ISH0613 / SunHo BioPharma - LARVOL DELTA

First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics (clinicaltrials.gov) - P1 | N=26 | Not yet recruiting | Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd.

First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus